Background for History
A novel, one-time cure for chronic HBV will use a new gene editing technology and offer a game-changing solution compared to HBV drugs available today
-
CRISPR-Cas9 technology that recognize the DNA sequence for two HBV-related targets will be used. See below explanation of mechanism of CRISPR-Cas9, the History of Gene Editing tab, and the CRISPR-Cas9 Prototype tab.
-
HBV therapies approved today are either highly toxic interferon or lifetime daily anti-virals drugs. Neither type of drug cures HBV. See the History of HBV Treatments tab.
Hepativir-B uses genetic editing technologies to inhibit two HBV-related targets
How does CRISPR-Cas9 work?
CRISPR-Cas9 is a genetic editing tool that can delete and insert genetic sequences. Hepativir-B targets the genes for the NTCP receptor and HBx protein.
The first step is the single guide RNA (sgRNA) binding to the target sequence. See the CRISPR-CAS9 Prototype tab for how to design specific sgRNAs.
Next, the Cas9 enzyme binds to the guide RNA.
Then the Cas9 enzyme cuts both strands of the target DNA.
Finally, the cut is repaired, thus introducing the new genetic mutation.